Business Context and Reporting Period
Company: Alcon, Inc.
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: Fourth Quarter and Full Year ended December 31, 2002
Release Date: February 19, 2003
Business Overview: Alcon is the world's leading eye care company, developing and marketing pharmaceuticals, surgical equipment, devices, and contact lens care solutions.
Key Financial Metrics
| Metric | Q4 2002 | Q4 2001 | Full Year 2002 | Full Year 2001 |
|---|---|---|---|---|
| Global Sales | $749.2 million | $670.6 million | $3,009.1 million | $2,747.7 million |
| Net Earnings | $85.0 million | $57.0 million | $466.9 million | $315.6 million |
| Diluted EPS | $0.26 | $0.19 | $1.53 | $1.05 |
| Gross Profit Margin | 68.9% | 70.4% | 70.3% | 70.9% |
| Effective Tax Rate | 23.7% | 38.6% | 31.1% | 38.6% |
| Cash & Equivalents (Dec 31, 2002) | $967.9 million | |||
| Total Debt (Dec 31, 2002) | $1,876.7 million | |||
| Net Debt (Dec 31, 2002) | $908.8 million |
Material Changes vs. Prior Period
- Revenue Growth: Q4 sales increased 11.7% (11.1% excluding FX); Full year sales increased 9.5% (10.0% excluding FX).
- Profitability: Q4 net earnings rose 49.1%; Full year net earnings rose 47.9%. Pro-forma earnings (adjusted for accounting changes and non-recurring items) increased 39.1% in Q4 and 35.0% for the full year.
- Margin Compression: Gross profit margins declined slightly due to inventory/equipment write-offs from the SKBM microkeratome recall, foreign exchange fluctuations, and product mix shifts.
- Expense Increases: SG&A expenses rose as a percentage of sales in Q4 due to recall costs and sales force expansion. R&D expenses increased 19.1% in Q4 and 11.6% for the full year, driven by clinical studies for age-related macular degeneration.
- Segment Performance:
- Pharmaceuticals: Strong growth driven by Travatan (up 240% in Q4) and Patanol (up 32.5% in Q4).
- Surgical: Overall growth of 8.3% in Q4, but refractive revenues declined 26.3% due to weak consumer confidence.
- Consumer Eye Care: Modest growth of 7.3% in Q4, led by Opti-Free solutions.
Guidance, Outlook, and Risks
- 2003 Guidance: Sales expected between $3,270 million and $3,300 million; Diluted EPS expected between $1.82 and $1.85.
- Dividend Proposal: Board proposed a dividend of 0.45 Swiss francs per share, payable June 4, 2003, representing approximately 22% of 2002 net earnings.
- Product Pipeline: Management highlighted a rich pipeline with three new pharmaceutical products launching in 2003 and expansion of the U.S. sales force.
- Unusual Items & Accounting Changes:
- Adoption of FASB Statement #142 eliminated goodwill amortization in 2002.
- One-time pre-tax charge of $25.9 million for the SKBM microkeratome recall.
- One-time pre-tax charge of $22.6 million related to changes in the deferred compensation plan.
- Risks: Forward-looking statements are subject to risks including product development delays, reimbursement changes, competition, currency fluctuations, litigation, and supply disruptions.
Investor Verification Checklist
- Verify the impact of the SKBM microkeratome recall on future surgical product margins and litigation exposure.
- Confirm the sustainability of pharmaceutical growth rates, specifically for Travatan and Patanol, as they mature.
- Monitor the refractive surgery segment for signs of recovery given the 20.9% full-year decline.
- Assess the company's ability to meet 2003 EPS guidance amidst rising R&D and SG&A costs.
- Review the net debt-to-total capital ratio (48%) and liquidity position given the high level of short-term borrowings ($1,772.8 million).